Navigation Links
Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
Date:6/17/2009

TEL AVIV, Israel, June 17 /PRNewswire/ -- A recent clinical study using Pollogen's regen(TM) device- the latest aesthetic solution powered by 3rd generation TriPollar(TM) technology, confirms the safety and efficacy of TriPollar(TM) technology in reducing fat and collagen remodeling. The peer reviewed paper entitled "Clinical and histopathological results following TriPollar(TM) radiofrequency skin treatments", authored by Dr. Haim Kaplan and Dr. Andrea Gat, has been published in the June issue of the Journal of Cosmetic and Laser Therapy (Volume 11, Issue 2 June 2009 , pages 78 - 84). The abstract is available online at: http://www.informaworld.com/smpp/content~db=all~content=a910865593?words=kapl an&hash=843258562

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

The study provides further evidence that TriPollar(TM) technology is a safe and effective non-invasive solution for skin tightening and body reshaping.

The study involved twelve patients who underwent an average of seven weekly treatment sessions on different body areas including the face, neck, arms, hands and abdomen. One patient consented to a series of TriPollar(TM) treatments prior to her scheduled abdominoplasty and a controlled histological analysis was performed on skin samples taken during the surgery. The histopathological examination revealed marked differences between the treated and non- treated abdominal skin areas. An increase of 49% in dermal thickness due to neo collagen regeneration, focal thickening and remodeling of collagen fibers and focal shrinkage of fat cells were measured following the TriPollar(TM) treatments.

Patient satisfaction was also measured and the study confirmed clear satisfaction with achieved clinical results.

Dr. Kaplan stated: "The regen TriPollar device is an RF system that can safely and effectively be used for body contouring, particularly on the abdomen, thighs and arms, as well as for the treatment of cellulite, skin laxity and facial wrinkles, given the correct indication. Application of this treatment modality is simple, non-invasive and extremely safe on all skin types. Clinical and histological results have been documented and appear to be maintained for at least several months following a typical treatment course of 8 weekly sessions."

"We are very excited about the latest clinical results that further confirm the marked efficacy of TriPollar(TM) technology in treating a wide variety of aesthetic needs- body contouring, facial rejuvenation and cellulite reduction. The painless, non-invasive solution offers an ideal alternative to surgery-averse patients. Pollogen is dedicated to continuing to develop products that enhance the wellbeing of patients worldwide" commented Dr. Zion Azar Pollogen's Chairman and CEO.

About Pollogen:

Pollogen Ltd. develops, manufactures and markets professional medical aesthetic devices, powered by the TriPollar(TM) 3rd generation Radio Frequency (RF) technology. Invented and perfected by Pollogen, proprietary TriPollar(TM) technology powers a full line of clinically-proven, non-invasive and non-surgical treatment platforms for wrinkles, cellulite, circumference reduction and skin tightening. The flagship aesthetic devices, apollo(TM) and regen(TM) offer customers clinically-proven, safe and effective anti-aging beauty treatments that deliver immediate and long-lasting results. To learn more, please visit the Pollogen website at http://www.pollogen.com

    Contact:

    Abigail Marks
    Tel: +972-54-244-5807
    E-mail: abigail_m@pollogen.com



'/>"/>
SOURCE Pollogen Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
2. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
3. New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
4. When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research
5. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
8. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
9. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
10. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
11. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified ... year ended 31 December 2016 compared with the previous corresponding period. ... viewed here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: ... 2015: $15.7m; up 11%) Profit before tax of ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis ... the global Oesophageal Cancer market. The research answers the ... drugs marketed for Oesophageal Cancer and their clinical attributes? How are ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Healthcare Associates of McKinney announced today that ... at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in ... , As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... Charlevoix, MI (PRWEB) , ... February 24, 2017 ... ... venue in Charlevoix, once again hosted their Military Wedding Giveaway, with the ... be hosted by Castle Farms with services generously donated from local vendors: A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare ... audience, will be participating in Rare Disease Day events, hosted by the Rare ... Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an approved content provider for the National Institute for Health and Care ... social care-related organizations in the National Health Service (NHS) to search, order and ...
Breaking Medicine News(10 mins):